查看购物车
  • Traditional Chinese
  • English
  • Japanese
北美阿片类药物市场预测至 2030 年 - 区域分析 - 按产品、应用、给药途径和配销通路
市场调查报告书
商品编码
1637657

北美阿片类药物市场预测至 2030 年 - 区域分析 - 按产品、应用、给药途径和配销通路

North America Opioids Market Forecast to 2030 - Regional Analysis - by Product, Application, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 90 Pages | 订单完成后即时交付

价格

2022年北美阿片类药物市值为49.2189亿美元，预计2030年将达到54.4988亿美元；预计2022年至2030年复合年增长率为1.3%。

老年人口的增加推动了北美阿片类药物市场

大多数老年人患有慢性疼痛，导致日常生活能力下降。老年人普遍患有骨关节疾病、关节炎、癌症和其他引起疼痛的慢性疾病。根据世界卫生组织（WHO）2018年2月的资料，预计到2050年，老年人口资料增加22%，而2015年这一数字为12%。 %。美国、加拿大、英国、法国、德国和日本等已开发国家，以及中国、印度和韩国等发展中国家，老年人口也在经历显着增长，这是由于医疗保健设施改善和环境改善所推动的。保健服务；这导致这些地区的预期寿命延长。根据 NCBI 杂誌报道，强效阿片类药物处方在老龄化人群中更为普遍，并且在该年龄组中增长速度最快。根据医疗保健研究和品质机构的数据，2020 年至2021 年期间，美国65 岁及以上成年人中平均有12.8% 至少开过一张门诊阿片类药物处方，4.4% 的人在2020 年至2021 年间开有四种或更多阿片类药物处方。此外，符合贫穷类别（6.1%）、低收入类别（6.6%）和中等收入类别（5.2%）资格的老年人比高收入类别（2.6%）的老年人更有可能获得2020 年至2021 年期间配发四种或更多鸦片类药物处方。因此，世界各地老年人口的成长推动了北美阿片类药物市场的成长。

北美阿片类药物市场概况

以鸦片类药物为基础的止痛药是中度至重度关节炎疼痛患者骨科照护的基石。根据美国疾病管制与预防中心 (CDC) 2023 年 10 月发布的关节炎盛行率资料，2019 年至2021 年间，美国近21.2% 的成年人（即5,320 万人）患有医生诊断的关节炎，而这一数字预计到 2040 年将达到 7,840 万人。

另一方面，阿片类药物过量案例的激增正在影响北美阿片类药物市场的成长。根据世界卫生组织（WHO）关于阿片类药物过量的统计数据，2019年美国有70,630人因药物过量死亡。疾病预防控制中心也估计，1999 年至 2021 年间，该国约有 28 万人死于处方阿片类药物过量。 2021 年，全国所有阿片类药物过量死亡中近 21% 涉及处方阿片类药物。由于阿片类药物过量导致的病例数和死亡率不断增加，美国疾病管制与预防中心(CDC) 在2017 年将这种情况列为全国性突发公共卫生事件。药物危机，其中包括过度使用、误用/滥用的情况迅速增加，以及归因于阿片类药物类别的过量死亡。为了解决阿片类药物危机并防止故意滥用，美国食品和药物管理局 (FDA) 鼓励开发具有防滥用配方 (ADF) 的处方阿片类药物。 FDA 于2021 年3 月批准了酒石酸氢可酮。滥用。此外，为了解决未满足的医疗需求，美国的药物审批增加。因此，北美阿片类药物市场参与者一直专注于产品批准和改进等策略，以扩大其产品组合，以及扩张和合併以提高其市场份额。 2020 年3 月，Trevena, Inc. 的OLINVYK（oliceridine）获得FDA 批准，这是一种阿片类激动剂，适用于治疗成人中度至重度急性疼痛，特别是当疼痛严重到需要静脉注射阿片类药物时。

北美阿片类药物市场收入及 2030 年预测（百万美元）

北美阿片类药物市场细分

北美阿片类药物市场按产品、应用、给药途径、配销通路和国家分类。

根据产品，北美鸦片类药物市场分为速释短效鸦片类药物和缓释长效型鸦片类药物。 2022年，速释短效鸦片类药物细分市场占据了更大的市场份额。芬等。缓释长效型鸦片类药物进一步细分为羟考酮、芬太尼、吗啡、美沙酮等。

从应用来看，北美鸦片类药物市场分为疼痛管理、麻醉、止泻、止咳、戒瘾等。 2022 年，疼痛管理领域占据最大的市场。

依给药途径，北美鸦片类药物市场分为口服、注射和经皮贴片。 2022 年，口腔细分市场占据最大的市场。

依配销通路划分，北美阿片类药物市场分为医院药房和零售药房。 2022年，医院药局部门将占据更大的市场份额。

按国家/地区划分，北美阿片类药物市场分为美国、加拿大和墨西哥。 2022 年，美国在北美阿片类药物市场份额中占据主导地位。

Purdue Pharma LP、Endo International plc、Mallinckrodt Plc、Collegium Pharmaceutical Inc、Neuraxpharm Pharmaceuticals SL、Hikma Pharmaceuticals Plc、Rusan Pharma Ltd、Trevena Inc 和 Teva Pharmaceutical Industries Ltd 是北美阿片类药物市场的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美鸦片类药物市场 - 主要市场动态

  • 北美阿片类药物市场 - 主要市场动态
  • 市场驱动因素
    • 慢性疼痛发生率激增
    • 老年人口增加
  • 市场限制
    • 药物滥用增加
  • 市场机会
    • 市场参与者的策略性倡议
  • 未来趋势
    • 政府措施重点关注开发预防和治疗阿片类药物过量和疾病的药物
  • 驱动因素和限制的影响：

第 5 章：鸦片类药物市场 - 北美分析

  • 北美阿片类药物市场收入，2020-2030
  • 北美阿片类药物市场预测分析

第 6 章：北美鸦片类药物市场分析 - 按产品

  • 速释短效鸦片类药物
  • 缓释长效型鸦片类药物

第 7 章：北美鸦片类药物市场分析 - 按应用

  • 疼痛管理
  • 麻醉
  • 抑制腹泻
  • 止咳
  • 戒瘾
  • 其他的

第 8 章：北美鸦片类药物市场分析 - 按给药途径

  • 口服
  • 可注射
  • 透皮贴剂

第 9 章：北美鸦片类药物市场分析 - 按配销通路

  • 医院药房
  • 零售药局

第 10 章：北美鸦片类药物市场 - 国家分析

  • 美国
  • 加拿大
  • 墨西哥

第 11 章：产业格局

  • 概述
  • 阿片类药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 12 章：公司简介

  • Purdue Pharma L.P.
  • Endo International plc
  • Mallinckrodt Plc
  • Collegium Pharmaceutical, Inc.
  • Neuraxpharm Pharmaceuticals SL
  • Hikma Pharmaceuticals Plc
  • Rusan Pharma Ltd
  • Trevena, Inc.
  • Teva Pharmaceutical Industries Ltd

第 13 章：附录

Product Code: BMIRE00031020

The North America opioids market was valued at US$ 4,921.89 million in 2022 and is expected to reach US$ 5,449.88 million by 2030; it is estimated to register a CAGR of 1.3% from 2022 to 2030.

Increasing Geriatric Population Fuels North America Opioids Market

The majority of older people live with chronic pain, resulting in reduced strength to carry out their daily routine. The geriatric population widely suffers from bone and joint disorders, arthritis, cancer, and other chronic disorders causing pain. According to the World Health Organization (WHO) data from February 2018, the geriatric population is estimated to grow by 22% by 2050 compared with 12% in 2015. The data also stated that low- and middle-income countries would account for nearly 80% of this surge. Developed countries such as the US, Canada, the UK, France, Germany, and Japan, and developing countries such as China, India, and South Korea are also experiencing significant growth in the geriatric population, which is driven by improved healthcare facilities and better healthcare services; this has resulted in increased life expectancy in these regions. According to NCBI Journal, strong opioid prescribing is more prevalent in the aging population, growing at the fastest rate in this age group. As per the Agency for Healthcare Research and Quality, 12.8% of adults aged 65 and older, on average, had at least one outpatient opioid prescription, and 4.4% had four or more opioid prescriptions during 2020-2021 in the US. Furthermore, older adults qualifying under the poor category (6.1%), low-income category (6.6%), and middle-income category (5.2%) were more likely than those grouped under the high-income category (2.6%) to get four or more opioid prescription fills during 2020-2021. Thus, the growing geriatric population across the world drives the growth of the North America opioids market.

North America Opioids Market Overview

Opioid-based pain medications are a cornerstone of orthopedic care for patients with moderate to severe arthritis pain. As per data released by the Centers for Disease Control and Prevention (CDC) in October 2023 on arthritis prevalence, nearly 21.2% of adults in the US (i.e., 53.2 million people) had doctor-diagnosed arthritis during 2019-2021, and the number is projected to reach 78.4 million by 2040. The demand for opioids is increasing for pain management with the growing cases of arthritis.

On the other hand, the surging cases of opioid overdose are affecting the growth of the North America opioids market. As per the World Health Organization (WHO) statistics on opioid overdose, there were 70,630 deaths due to drug overdose in 2019 in the US. The CDC also estimated that ~280,000 people in the country died from the overdose of prescription opioids during 1999-2021. In 2021, nearly 21% of all opioid overdose deaths in the country involved a prescription opioid. Due to the increasing number of cases and mortality rate from opioid overdoses, the CDC labeled the situation as a nationwide Public Health Emergency in 2017. This situation was also referred to as the opioid crisis, which included the rapid increase in overuse, misuse/abuse, and overdose deaths attributed to the class of opioid drugs. To tackle the situation of opioid crisis and prevent intentional misuse, the Food and Drug Administration (FDA) is encouraging the development of prescription opioids with abuse-deterrent formulations (ADFs). The FDA approved hydrocodone bitartrate in March 2021. It is the first FDA-approved generic opioid with an ADF, and the medication has properties that are expected to reduce the misuse of the drug when chewed and then taken orally, crushed and snorted, or injected. Further, to address the unmet medical needs, there has been an increase in medication approval in the US. Thus, the North America opioids market players have been focusing on strategies such as product approvals and advancements to broaden their product portfolio, and expansions and mergers to improve their market share. In March 2020, Trevena, Inc. received FDA approval for OLINVYK (oliceridine), an opioid agonist indicated for the management of moderate to severe acute pain in adults, especially when the pain is severe enough to require an intravenous opioid.

North America Opioids Market Revenue and Forecast to 2030 (US$ Million)

North America Opioids Market Segmentation

The North America opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the North America opioids market is bifurcated immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the North America opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the North America opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the North America opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the North America opioids market is segmented into the US, Canada, and Mexico. The US dominated the North America opioids market share in 2022.

Purdue Pharma LP, Endo International plc, Mallinckrodt Plc, Collegium Pharmaceutical Inc, Neuraxpharm Pharmaceuticals SL, Hikma Pharmaceuticals Plc, Rusan Pharma Ltd, Trevena Inc, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America opioids market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Opioids Market - Key Market Dynamics

  • 4.1 North America Opioids Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Surging Chronic Pain Incidence
    • 4.2.2 Increasing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Increasing Drug Abuse
  • 4.4 Market Opportunities
    • 4.4.1 Strategic Initiatives by Market Players
  • 4.5 Future Trends
    • 4.5.1 Government Initiatives Focusing on Development of Medication to Prevent and Treat Opioid Overdose and Disorder
  • 4.6 Impact of Drivers and Restraints:

5. Opioids Market - North America Analysis

  • 5.1 North America Opioids Market Revenue (US$ Million), 2020-2030
  • 5.2 North America Opioids Market Forecast Analysis

6. North America Opioids Market Analysis - by Product

  • 6.1 Immediate Release Short Acting Opioid
    • 6.1.1 Overview
    • 6.1.2 Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.1.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • 6.2 Extended Release Long-Acting Opioid
    • 6.2.1 Overview
    • 6.2.2 Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.2.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. North America Opioids Market Analysis - by Application

  • 7.1 Pain Management
    • 7.1.1 Overview
    • 7.1.2 Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Anesthesia
    • 7.2.1 Overview
    • 7.2.2 Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Diarrhea Suppression
    • 7.3.1 Overview
    • 7.3.2 Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Cough Suppression
    • 7.4.1 Overview
    • 7.4.2 Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 De-Addiction
    • 7.5.1 Overview
    • 7.5.2 De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Opioids Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Injectable
    • 8.2.1 Overview
    • 8.2.2 Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Transdermal Patch
    • 8.3.1 Overview
    • 8.3.2 Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Opioids Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Opioids Market - Country Analysis

  • 10.1 North America Opioids Market - Country Analysis
    • 10.1.1 North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
      • 10.1.1.1 North America Opioids Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 United States: North America Opioids Market Breakdown, by Product
        • 10.1.1.2.2 United States: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.2.3 United States: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.2.4 United States: North America Opioids Market Breakdown, by Application
        • 10.1.1.2.5 United States: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.2.6 United States: North America Opioids Market Breakdown, by Distribution Channel
      • 10.1.1.3 Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Canada: North America Opioids Market Breakdown, by Product
        • 10.1.1.3.2 Canada: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.3.3 Canada: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.3.4 Canada: North America Opioids Market Breakdown, by Application
        • 10.1.1.3.5 Canada: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.3.6 Canada: North America Opioids Market Breakdown, by Distribution Channel
      • 10.1.1.4 Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Mexico: North America Opioids Market Breakdown, by Product
        • 10.1.1.4.2 Mexico: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.4.3 Mexico: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.4.4 Mexico: North America Opioids Market Breakdown, by Application
        • 10.1.1.4.5 Mexico: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.4.6 Mexico: North America Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Opioids Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Purdue Pharma L.P.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Endo International plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Mallinckrodt Plc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Collegium Pharmaceutical, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Neuraxpharm Pharmaceuticals SL
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Hikma Pharmaceuticals Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Rusan Pharma Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Trevena, Inc.
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Teva Pharmaceutical Industries Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Opioids Market Segmentation
  • Table 2. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 4. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 5. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 6. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 7. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 8. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 9. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
  • Table 10. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 11. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 12. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 13. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 14. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 15. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 16. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 17. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 18. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 19. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 20. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 21. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 22. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 23. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 24. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 26. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 27. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 28. Recent Organic Growth Strategies in Opioids Market
  • Table 29. Recent Inorganic Growth Strategies in the Opioids Market
  • Table 30. Glossary of Terms, Opioids Market

List Of Figures

  • Figure 1. North America Opioids Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Opioids Market Revenue (US$ Million), 2020-2030
  • Figure 4. North America Opioids Market Share (%) - by Product (2022 and 2030)
  • Figure 5. Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. North America Opioids Market Share (%) - by Application (2022 and 2030)
  • Figure 8. Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America Opioids Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 15. Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. North America Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 19. Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Opioids Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
  • Figure 22. North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 23. United States: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. Canada: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 26. Growth Strategies in Opioids Market